Saturday, May 7, 2022 12:30 PM – 1:15 PM ET Exhibit Hall, Workshop Room 3
Exhibitor Workshop: Miltenyi Biotec
Ultra-High Content Imaging Helps to Identify CAR Target Candidates Against Pancreatic Adenocarcinoma
- Daniel Schäfer Ph.D., Team Coordinator Cellular Immunotherapy
Chimeric antigen receptor (CAR) T cells have become a new pillar of cancer therapy. This therapy has been applied successfully in the treatment of some cancers of the bone marrow and blood. However, the remarkable success of CAR T cell therapies in liquid tumors has not yet been translated to solid malignancies. Using our innovative MICS technology, we identified four CAR targets among 371 antigens tested. This in turn resulted in the generation of 32 CARs whose potential was tested in vitro and in vivo. Efficacy in pre-clinical studies ranged from stabilized disease to complete tumor eradication.